Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 18

Results For "CAS"

1859 News Found

Accenture invests in Ryght AI to revolutionize clinical trials
Digitisation | December 16, 2025

Accenture invests in Ryght AI to revolutionize clinical trials

Ryght AI tackles these hurdles with its AI Site Twin platform


Sobi to acquire Arthrosi Therapeutics in $950 million deal, bolstering gout pipeline
Clinical Trials | December 16, 2025

Sobi to acquire Arthrosi Therapeutics in $950 million deal, bolstering gout pipeline

The drug is currently being evaluated in two fully recruited global Phase 3 studies for progressive and tophaceous gout, with results expected in 2026.


Lilly drug cuts risk of cancer progression, extends survival in advanced breast cancer trial
Clinical Trials | December 13, 2025

Lilly drug cuts risk of cancer progression, extends survival in advanced breast cancer trial

Updated results from the EMBER-3 study showed that the drug -- Inluriyo (imlunestrant) -- as a standalone treatment cut the risk of progression or death by 38%


Formation Bio snaps up global rights to next-gen CNS TYK2 inhibitor from Lynk Pharma
News | December 12, 2025

Formation Bio snaps up global rights to next-gen CNS TYK2 inhibitor from Lynk Pharma

LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure


New oral SERD from Roche delivers significant survival edge in early breast cancer
Clinical Trials | December 12, 2025

New oral SERD from Roche delivers significant survival edge in early breast cancer

At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival


Novo Nordisk completes acquisition of Akero Therapeutics
News | December 10, 2025

Novo Nordisk completes acquisition of Akero Therapeutics

Akero became a wholly owned subsidiary of Novo Nordisk


Viatris sells stake in Biocon Biologics for $815 million, regains global Biosimilars access
News | December 09, 2025

Viatris sells stake in Biocon Biologics for $815 million, regains global Biosimilars access

Biocon will acquire all of Viatris’ convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued Biocon shares


New study aims to improve mobility for millions with flat foot and knee osteoarthritis
Healthcare | December 08, 2025

New study aims to improve mobility for millions with flat foot and knee osteoarthritis

The launch of the study was on the occasion of the International Day of Persons with Disabilities


Halozyme wins German injunction blocking Merck’s Keytruda distribution
Biopharma | December 08, 2025

Halozyme wins German injunction blocking Merck’s Keytruda distribution

While Merck can appeal, Halozyme said it expects the order to hold